News
In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option
The 2012 Deals of Distinction™ Award was presented to National Institutes of Health (NIH) along with the University of Illinois at Chicago (UIC), who jointly own one patent family, and to Gilead Sciences (Gilead) for license agreements granted to the Medicines Patent Pool, a newly established
In a recently released report, the NIH details its plans for Accelerating Technology Transfer and Commercialization in Support of High Growth Business. The Plan is a response to the October 28, 2011 Presidential Memorandum ( http://1.usa.gov/uHoAA4) that required federal agencies to streamline
Researchers have launched a clinical trial at the NIH Clinical Center to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). DEX-M74, based on an NIH technology, is being developed through a collaboration between the